Biologics News

Nexxt Spine LLC recently announced the development of NanoMatrixx, a new porous bioactive titanium material designed to be used in intervertebral fusion.

DePuy Synthes Trauma recently announced the U.S. launch of CONFORM Flex with Q-PACK technology, the company’s new trauma-related offering for fixation of the foot and ankle and hand and wrist.

Histogenics Corporation has announced a supply agreement between the company and Collagen Solutions Ltd. of the United Kingdom.

Wright Medical has announced the completion of the previously announced merger between Wright Medical and Tornier N.V.

The Subcommittee on Primary Health and Retirement Security met on Thursday, September 17 for a hearing on the implementation of biosimilar agents with Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA, and among other questions about interchangeability and safety, some senators questioned the lack of action in the issuance of guidance documents.

Xtant Medical announced their subsidiary, Bacterin International, has received a U.S. patent for demineralized bone matrices derived from cortical bone. The patent will include Bacterin’s OsteoSTX, OsteoWrap and OrbitalWrap HD product lines.

Spine surgery in the summer may pose a higher risk of surgical site infections for patients, according to the results of a recently published study.

In regard to your article “An 82-year-old man with right hip trauma” featured in Orthopedics Today, June 2015, by Michael R. Conti Mica, MD; and Mitchell Bernstein, MD, FRCSC, it is unfortunate the authors failed to mention this patient did not actually have “hip trauma,” but sustained this injury from a standing-level fall. By definition, this was a fragility fracture and makes the patient’s accurate diagnosis severe established osteoporosis with pathologic fracture.

COPENHAGEN, Denmark — Condoliase, an enzyme that degrades glycosaminoglycans, was well-tolerated by patients who received it as a treatment for lumbar disc herniations, according to a speaker here.

In agreement with the FDA’s recent draft guidance on nonproprietary naming of biological products, six physician groups collectively sent a letter to CMS Acting Administrator Andrew Slavitt on Tuesday urging CMS to adopt unique billing codes for biosimilars, according to a press release.